Encouraging Initial Clinical Data Presented from Ph 1 Trial of THE001
“Presenting the first clinical data for THE001 in combination with regional hyperthermia is an important milestone for Thermosome,” said Dr. Frank Hermann, CMO of Thermosome. “The data not only confirm the galenic principle of thermosensitive liposomes releasing almost complete doxorubicin upon heat-triggered regional hyperthermia in humans, but also the safe application to date with no formulation-related adverse events. In addition, the first signs of clinical activity in these heavily pre-treated palliative patients are very encouraging and support our efforts to accelerate the clinical development program in soft tissue sarcoma.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data